Recently,PaceMate, Inc., a provider of cardiac remote monitoring solutions, announced that it has successfully acquired Paceart Optima, Medtronic's localized cardiac workflow solution in China.However, the financial details of the transaction have not been disclosed to the public.

PaceMate, as an innovator in cardiac health data management solutions, has gained widespread recognition in recent years for its remote monitoring technology.The integration of the Paceart Optima system is expected to add nearly 1,000 clinic partners for Medtronic globally.

For Medtronic, this divestiture aligns with its overall strategy to focus resources on core innovation and advancements in treatment.PaceMate further solidifies its market leadership and expands its global influence by increasing the depth and breadth of its services. Moving forward, Medtronic's Cardiac Rhythm Management (CRM) business will work closely with PaceMate to ensure a smooth transition.

Medtronic Paceart Optima is an integrated workflow solution designed for the efficient aggregation and management of patient cardiac device data.Supports the collection, storage, and retrieval of data from programmers and remote monitoring systems of all major cardiac device manufacturers (such as Medtronic, Abbott, Boston Scientific, etc.), ensuring comprehensiveness and convenience in data management.

According to reports,Paceart Optima can comprehensively process data from implanted devices, clinic examinations, and remote transmissions. Regardless of whether the data comes from hospitals, clinics, or patients' home monitors, it can be smoothly imported and stored in the Paceart database.And seamlessly transmit the data to the EHR system, achieving comprehensive data integration and convenient access.

The first generation of this system was developed in 1985, and it has accumulated over 30 years of experience in equipment management to date.Capable of integrating with 28 Electronic Health Record (EHR) systems, the Device Encyclopedia includes over 3,300 entries.

Cybersecurity Vulnerability

Notably, in July 2023,Medtronic reported to the Cybersecurity and Infrastructure Security Agency (CISA) the discovery of cybersecurity vulnerabilities in the Paceart Optima system.This vulnerability is classified as a critical high-risk vulnerability, with a CVSS score of 9.8.

CISA pointed out: If medical institutions have enabled the optional Paceart Messaging Service in the Paceart Optima system, unauthorized users may exploit this vulnerability by sending specially crafted messages to the Paceart Optima system, executing remote code or performing a Denial of Service (DoS) attack.Remote code execution may lead to the deletion, theft, or modification of cardiac device data in the Paceart Optima system, or the use of the Paceart Optima system for further network penetration.DoS attacks may cause the Paceart Optima system to become slow or unresponsive.

Subsequently, Medtronic resolved this issue through a software update.At the same time, to immediately mitigate the risk, Medtronic provided steps to manually disable message services and message queuing on the application server.

Data shows that PaceMate, Inc. was founded in 2015 as a medical technology company headquartered in Florida, USA.Offering the most comprehensive end-to-end platform in the industry, supporting all types of cardiac devices from implantable devices, mobile monitors, heart failure devices to remote patient monitoring.

The company's flagship product, PaceMateLIVE™, is widely recognized as the premier remote cardiac monitoring software.With seamless integration with Electronic Health Record platforms (EHR), it helps medical institutions optimize operations, improve the quality of patient care, and promote the development of cutting-edge research.

Remote Cardiac Monitoring Has Become the Gold Standard of Care, but It Also Adds Extra Pressure on Already Overburdened Clinics. Today’s clinics face significant challenges, such as staff shortages and the influx of massive amounts of data.PaceMateLIVE can integrate data from all cardiac devices onto a single platform, helping hospitals reduce workload through intelligent automation features such as automatic triage and automated scripting.

At the same time, the company has developed a full set of flexible solutions based on this platform, including software, patient communication, and clinical service support.Institutions can customize based on their own EHR, workflows, and specific needs. Improve patient outcomes through real-time clinical information and streamline billing and reporting processes through intelligent automation.

It is not difficult to see that PaceMateLIVE and Paceart Optima belong to the same track of products, but their focuses are different.

It is expected that the combination of the two in the future will bring unprecedented improvements to remote cardiac monitoring and provide healthcare providers with a more powerful and comprehensive solution.At the same time, further consolidate PaceMate's leading position in the industry. Currently, PaceMateLIVE has covered more than 335 clinics, and it is expected that the acquisition will add nearly 1,000 clinic partners.

The remote cardiac mobile monitoring system is a cardiac health monitoring tool based on telemedicine technology, typically consisting of a cardiac testing data processing platform located in the hospital and a cardiac monitor carried by the patient.

The cardiac monitor has the functions of real-time analysis and early warning, recording and storage, and sending test data.Able to detect high-risk abnormal conditions in patients at the first time and notify them promptly,To achieve early detection, early intervention, and early treatment, reduce the occurrence of acute events, and improve the efficiency of overall medical care.

According to the American Heart Association, nearly half of American adults suffer from cardiovascular disease (CVD). It is estimated that nearly 6 million adults currently have heart failure, and this number is expected to increase by 40% by 2035.By 2035, it is projected that more than 130 million adults (45.1% of the U.S. population) will have some type of cardiovascular disease.

Due to the increase in the incidence of cardiovascular diseases and the aging population, the demand for remote monitoring has surged in recent years.The market size reached approximately USD 2 billion in 2022 and is expected to continue growing at a compound annual growth rate (CAGR) of about 12.5%, potentially exceeding USD 6 billion by 2028.

Currently, globally operating companies in the remote cardiac mobile monitoring system sector include Medtronic andIn addition to PaceMate,YesAbbott, AMC Health, Biotronik, Boston Scientific, GE Healthcare, Honeywell, Philips Healthcare, OSI SystemsAnd other companies. Relevant companies in China includeLepu Medical, Shenzhou Wisdometc.

In the future, as global healthcare policies shift towards preventive care, more regions will increase support for telemedicine solutions, driving the continuous growth of the remote cardiac mobile monitoring system market. Meanwhile, as PaceMate expands its global business footprint, it is expected to bring more intelligent and personalized solutions for the remote monitoring and management of heart disease patients.

So, what are PaceMate's next steps to further transform the global cardiac care landscape? What innovative technologies will emerge from the combination of the products of these two powerful companies in the future? Instrument Family will continue to follow up.

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

"King of Rigid Endoscopes" Joins Hands with "Giant of Flexible Endoscopes"

Johnson & Johnson, Multiple Major Personnel Changes

Giant of Respiratory Devices, "Dismantled"

One Province Issues 136 Class B Licenses: 68 Linear Accelerators

"Blue Giant" Returning to Medical Field, Might It Withdraw from China?

Evaporated nearly 140 billion, has China's largest medical aesthetics company imploded?

$340 Million: Medical Device Giant Enters This Field

Minimally Invasive Surgery "Unicorn" Halts STAR Market IPO

The 6th Deal This Year: Orthopedic Leader Makes Another Acquisition

Varian Greater China, Leadership Change

BusinessBusiness cooperation email: qxzj@landianyiliao.com